Carbetocin is a long-acting synthetic agonist analogue of human oxytocin, with antihemorrhagic and uterotonic activities. Upon administration, carbetocin targets, binds to and activates peripheral oxytocin receptors that are present on the smooth musculature of the uterus. This causes uterus contractions and prevents excessive bleeding after childbirth, particularly following Cesarean section, and may be used to decrease blood loss during hysteroscopic myomectomy.
CAT No: R1961
CAS No: 37025-55-1
Synonyms/Alias: Carbetocin;37025-55-1;Pabal;Carbetocino;Carbetocinum;carbetocine;Carbetocina;CHEBI:59204;Carbetocinum [INN-Latin];Carbetocino [INN-Spanish];Duratocin (TN);LV-101;deamino-2-O-methyltyrosine-1-carbaoxytocin;88TWF8015Y;CARBETOCIN [MI];1-butanoic acid-2-(O-methyl-L-tyrosine)-1-carbaoxytocin;CARBETOCIN [INN];1-Butyric acid-2-(3-(p-methoxyphenyl)-L-alanine)oxytocin;CARBETOCIN [USAN];CARBETOCIN [MART.];CARBETOCIN [WHO-DD];Carbetocin [USAN:INN:BAN];UNII-88TWF8015Y;FE 992097;FE-992097;DTXSID90897527;EINECS 253-312-6;1-Carbaoxytocin, 1-butanoic acid-2-(O-methyl-L-tyrosine)-;Carbetocinum (INN-Latin);Carbetocino (INN-Spanish);CARBETOCIN (MART.);(2S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]-1-[(3R,6S,9S,12S,15S)-6-(2-amino-2-oxoethyl)-9-(3-amino-3-oxopropyl)-12-[(2S)-butan-2-yl]-15-[(4-methoxyphenyl)methyl]-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentazacycloicosane-3-carbonyl]pyrrolidine-2-carboxamide;1-Buttersaeure-2-(3-(4-methoxyphenyl)-L-alanin)oxytocin;1-Carboxytocin, 1-butanoic acid-2-(O-methyl-L-tyrosine)-;dcomot;(2S)-2-{[(2S)-1-{[(3R,6S,9S,12S,15S)-12-[(2S)-butan-2-yl]-9-(2-carbamoylethyl)-6-(carbamoylmethyl)-15-[(4-methoxyphenyl)methyl]-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentaazacycloicosan-3-yl]carbonyl}pyrrolidin-2-yl]formamido}-N-(carbamoylmethyl)-4-methylpentanamide;1-{[(3R,6S,9S,12S,15S)-6-(2-amino-2-oxoethyl)-9-(3-amino-3-oxopropyl)-12-[(2S)-butan-2-yl]-15-(4-methoxybenzyl)-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentaazacycloicosan-3-yl]carbonyl}-L-prolyl-L-leucylglycinamide;GLYCINAMIDE, N-(4-MERCAPTO-1-OXOBUTYL)-O-METHYL-L-TYROSYL-L-ISOLEUCYL-L-GLUTAMINYL-L-ASPARAGINYL-L-CYSTEINYL-L-PROLYL-L-LEUCYL-, CYCLIC (1->5)-THIOETHER;O-METHYL-N-(4-SULFANYLBUTANOYL)-L-TYROSYL-L-ISOLEUCYL-L-GLUTAMINYL-L-ASPARAGINYL-L-CYSTEINYL-L-PROLYL-L-LEUCYL-GLYCINAMIDE CYCLIC (1->5)-THIOETHER;Carbetocin?;C45H69N11O12S;(2S)-2-(((2S)-1-(((3R,6S,9S,12S,15S)-12-((2S)-butan-2-yl)-9-(2-carbamoylethyl)-6-(carbamoylmethyl)-15-((4-methoxyphenyl)methyl)-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentaazacycloicosan-3-yl)carbonyl)pyrrolidin-2-yl)formamido)-N-(carbamoylmethyl)-4-methylpentanamide;(2S)-N-((2S)-1-((2-amino-2-oxoethyl)amino)-4-methyl-1-oxopentan-2-yl)-1-((3R,6S,9S,12S,15S)-6-(2-amino-2-oxoethyl)-9-(3-amino-3-oxopropyl)-12-((2S)-butan-2-yl)-15-((4-methoxyphenyl)methyl)-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentazacycloicosane-3-carbonyl)pyrrolidine-2-carboxamide;1-(((3R,6S,9S,12S,15S)-6-(2-amino-2-oxoethyl)-9-(3-amino-3-oxopropyl)-12-((2S)-butan-2-yl)-15-(4-methoxybenzyl)-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentaazacycloicosan-3-yl)carbonyl)-L-prolyl-L-leucylglycinamide;MFCD01076600;Duratocin long acting;Carbetocin (Standard);1-deamino-1-monocarba-2-(Tyr(OMe))-oxytocin;SCHEMBL39224;Carbetocin (USAN/INN/BAN);oxytocin, 1-desamino-1-monocarba-(Tyr(OMe))(2)-;CHEMBL3301668;GTPL11169;H01BB03;NSTRIRCPWQHTIA-DTRKZRJBSA-N;DTXCID901326882;oxytocin, 1-desamino-1-monocarba-(tyrosine(O-methyl))(2)-;WHO 5014;BDBM50044677;HY-17573R;AKOS015994647;DB01282;FB19694;HS-2007;NCGC00485451-02;HY-17573;NS00056256;D07229;Carbetocin 100 microg/mL in Acetonitrile:Methanol;Q5037853;1-Deamino-1-monocarba-(0-2-methyltyrosine)-oxytocin;BRD-K56107812-001-01-7;1-Butanoic acid-2-(O-methyl-L-tyrosine)-1-carbaoxytocin;Deamino-2-O-methyltyrosine-1-carbaoxytocin;Depotocin;Carbetocin;253-312-6;
Chemical Name: (2S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]-1-[(3R,6S,9S,12S,15S)-6-(2-amino-2-oxoethyl)-9-(3-amino-3-oxopropyl)-12-[(2S)-butan-2-yl]-15-[(4-methoxyphenyl)methyl]-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentazacycloicosane-3-carbonyl]pyrrolidine-2-carboxamide
Quick InquiryCustom Peptide SynthesisPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C45H69N11O12S |
M.W/Mr. | 988.2 |
Sequence | [But1-Cys6] But-Tyr(Me)-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 |
Appearance | Solid powder |
Activity | Agonist |
Biological Activity | Carbetocin, an oxytocin (OT) analogue, is an oxytocin receptor agonist with a Ki of 7.1 nM. Carbetocin has high affinity to chimeric N-terminus (E1) of the oxytocin receptor (Ki=1.17 μM). Carbetocin has the potential for postpartum hemorrhage research. Carbetocin can crosse the blood-brain barrier and produces antidepressant-like activity via activation of oxytocin receptors in the CNS. |
Target | Oxytocin Receptor |
InChI | InChI=1S/C45H69N11O12S/c1-6-25(4)38-44(66)51-28(15-16-34(46)57)40(62)52-31(21-35(47)58)41(63)54-32(23-69-18-8-10-37(60)50-30(42(64)55-38)20-26-11-13-27(68-5)14-12-26)45(67)56-17-7-9-33(56)43(65)53-29(19-24(2)3)39(61)49-22-36(48)59/h11-14,24-25,28-33,38H,6-10,15-23H2,1-5H3,(H2,46,57)(H2,47,58)(H2,48,59)(H,49,61)(H,50,60)(H,51,66)(H,52,62)(H,53,65)(H,54,63)(H,55,64)/t25-,28-,29-,30-,31-,32-,33-,38-/m0/s1 |
InChI Key | NSTRIRCPWQHTIA-DTRKZRJBSA-N |
Canonical SMILES | CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSCCCC(=O)NC(C(=O)N1)CC2=CC=C(C=C2)OC)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N |
Isomeric SMILES | CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSCCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)OC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N |
1. The spatiotemporal control of signalling and trafficking of the GLP-1R
2. Peptides as Active Ingredients: A Challenge for Cosmeceutical Industry
4. Cationic cell-penetrating peptides are potent furin inhibitors
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.